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to test the robustness of the incremental effectiveness in economical analysis
carried out in patients with schizophrenia or bipolar disorders.
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OBJECTIVES: The objective of this study was to culturally adapt and validate the
Cornell-Brown Scale (CBS) for Quality of Life (QoL) in Dementia into Spanish.
METHODS: The original CBS was translated into Spanish by mean of a conceptual
equivalence approach, including forward and backward translations in duplicate.
Subjects with mild-to-moderate dementia were recruited and interviewed by a
psychologist who was trained in administering questionnaires to obtain sociode-
mographic information, health perceptions, depressive symptoms (GDS-15), func-
tional ability (Barthel Index), dementia severity (MMSE), specific QoL (CBS) and
generic QoL (WHOQOL-BREF). Participants were included if they had a diagnosis of
dementia according to DSM-IV criteria, a MMSE scoring  9, were living at home,
and had a known and stable caregiver with whom were living or had daily contact.
Acceptability, reliability, and validity were assessed using standard psychometric
methods. Exploratory factor analysis (EFA) was applied to analyze the dimensional
structure of the scale for the first time. RESULTS: A total of 100 persons with
dementia (66% female; 79.18 years) were recruited: 61% Alzheimer’s disease; 17%
vascular dementia; 14% mixed dementia; and 8% other dementia. Internal consis-
tency reliability was good (Cronbach=s  0.87). A priori hypotheses about the
relationship between CBS and the WHOQOL-BREF psychological domain and
GDS-15 were confirmed, indicating good criteria validity; Pearson=s r 0.570 and
-0.537, respectively. Discriminant validity was confirmed by the ability of the scale
to significantly differentiate between healthy and unhealthy and depressed and
non-depressed participants; but not between mild and moderate dementia. The
EFA showed a five-factor solution which accounted for 63.9% of the total variance of
CBS. CONCLUSIONS: The Spanish version of CBS showed good psychometric prop-
erties of validity and reliability to explore QoL in patients with mild-to-moderate
dementia in Spain. The factor structure of the CBS is reported for the first time.
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OBJECTIVES: To compare the efficacy and safety of tumour necrosis factor alpha
(TNF) inhibitors in the treatment of active ankylosing spondylitis (AS), in adult
patients naïve to biologic therapy. METHODS: A literature search was performed,
first focused on identifying health technology assessment reports (HTAR), meta-
analysis and systematic reviews. The databases searched were MEDLINE, EMBASE,
CRD, and the Cochrane Library. An exhaustive search of randomized controlled
trials (RCTs) that compared directly the TNF-inhibitors was also carried out in
MEDLINE and EMBASE. Both searches covered until November 2010. Two authors
independently selected the studies, assessed the quality, and performed the data
extraction, with disagreements resolved by a third reviewer until consensus was
obtained. In addition, an analysis of adjusted indirect comparisons (AIC) against a
common comparator was done using the method of Bucher et al. and the software
from the Canadian Agency for Drugs and Technologies in Health version 1.0.
RESULTS: A HTAR was included, it compared the clinical efficacy of infliximab,
etanercept and adalimumab associated with conventional treatment versus con-
ventional treatment and it also compared TNF-inhibitors between them. Five RCTs
were included to update the report. One study directly compared infliximab and
etanercept and the other four RCTs evaluated each of the TNF-inhibitors (inflix-
imab, etanercept, adalimumab and golimumab) versus placebo. In the AIC analysis
performed considering all the evidence available, no statistically significant differ-
ences in the ASAS20 response between infliximab, etanercept, adalimumab and
golimumab were found. Also, there were no statistically significant differences
between the TNF-inhibitors in the rate of serious infections or withdrawals due to
adverse events. CONCLUSIONS: Only one RCT directly compares two TNF inhibi-
tors. Therefore, in the absence of such trials, AIC are considered. No clinically
relevant differences are observed in the efficacy and safety between infliximab,
etanercept, adalimumab and golimumab in the treatment of adult patients with
AS.
PMS2
RISK AND COST OF INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS
TREATED WITH ANTI-TNF THERAPY IN ALBERTA, CANADA
Ohinmaa A1, Thanh NX1, Homik J2, Barnabe C3, Martin L3, Barr S3, Maksymowych W2
1Institute of Health Economics, Edmonton, AB, Canada, 2University of Alberta, Edmonton, AB,
Canada, 3University of Calgary, Calgary, AB, Canada
OBJECTIVES: To evaluate the risk of infection and associated healthcare costs in
Rheumatoid Arthritis (RA) patients treated with anti-Tumor Necrosis Factor (anti-
TNF) therapy in Alberta, Canada. METHODS: RA patients initiating anti-TNF ther-
apy between January 2004 and March 2009 in Edmonton and Calgary were followed
prospectively to identify treatment efficacy and adverse events. Clinical and self-
reported data was linked with provincial healthcare administrative databases. In-
fections (any and severe) were identified by using ICD 9 and 10 diagnosis codes. We
used Cox-regression to assess the risk of infection and linear regression to assess
the associated costs. RESULTS: The cohort consists of 1,086 patients (70% female,
mean age of 54 years) with a mean follow-up of 2.3 years. Seventy percent of
patients (n764) reported an infection during follow-up, while 4% (n42) suffered
a severe infection. Compared to patients on their first anti-TNF (n731), patients
who switched to another anti-TNF (n212), patients on DMARD (n75), and pa-
tients switched from DMARD to anti-TNF (n68) had similar Hazard Ratios (HR)
(p0.05) for both any and severe infection. Pre-existing lung disease (HR1.98,
p0.001) and heart disease (HR1.42, p0.037) increased, while male sex (HR 0.79,
p0.005) decreased the risk of any infection. The risk of a severe infection was
increased by underlying anemia (HR3.20, p0.018) and in those with longer dis-
ease duration (HR1.03, p0.032), but was reduced in patients with university-
level education (HR0.34, p0.018), and osteoarthritis (HR0.37, p0.035). In linear
regression, Log(cost) was significantly associated with higher baseline HAQ score
and longer disease duration and in patients who required a switch between anti-
TNF agents for inefficacy or adverse events. CONCLUSIONS: The risk of any or
severe infection did not differ significantly between treatment groups. Some pre-
existing diseases increased while being male and having university education de-
creased the infection risk. Healthcare cost variations between the treatment
groups were small.
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OBJECTIVES: Osteoporosis is a disease with accelerated bone loss associated with
an increased risk of fractures. Histomorphometry of bone biopsy specimens from
postmenopausal women with osteoporosis measures bone remodeling activities
which include both bone formation and resorption. This study compared the ef-
fects of two osteoporosis treatments (20 g/day teriparatide vs. 10 mg/day alendro-
nate) on bone remodeling using the principal components analysis (PCA) of bone
histomorphometry parameters. METHODS: Postmenopausal women with osteo-
porosis treated with either teriparatide or alendronate and completed iliac crest
bone biopsy at either the sixth or eighteenth month in the randomized, double-
blind Forteo Alendronate Comparator Trial were included in the analysis (teripa-
ratide: N12; alendronate: N9). Eighteen histomorphometric parameters were
grouped into either the formation (13) or resorption (5) category. Within each cat-
egory, the first principal component was estimated through the PCA and defined as
the principal formation component (PFC) and principal resorption component
(PRC). The summation of PFC and PRC was calculated to represent the overall level
of bone turnover. The difference between PFC and PRC was computed to determine
the imbalance between formation and resorption. RESULTS:The PFC accounted for
61.8% of total variance in the 13 formation parameters, and the PRC accounted for
70.4% of total variance in the 5 resorption parameters. The PFC was significantly
higher in the teriparatide group than in the alendronate group (0.68 vs. -0.95,
p0.0001), while the PRC was significantly lower in the alendronate group (-0.47 vs.
0.32, p0.05). The difference between the PFC and PRC was positive in the teripa-
ratide group and negative in the alendronate group. CONCLUSIONS: In postmeno-
pausal women with osteoporosis, teriparatide treatment stimulates both bone for-
mation and resorption, and formation dominates resorption. Treatment with
alendronate suppresses both bone formation and resorption, and resorption dom-
inates formation.
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OBJECTIVES: The objective was to determine if the effectiveness of collagenase
clostridium histolyticum (XIAFLEX, CCH) in real-world settings is comparable to
the efficacy demonstrated in the clinical trials. METHODS: A retrospective chart
review was conducted at selected sites. Charts of each patient treated with CCH in
2010 were abstracted. Effectiveness results were compared to efficacy findings
from the clinical registration trial (CORD-I)1 on 1) final contracture angle, 2) change
in contracture, 3) final range of motion, and 4)change in range of motion, with
means of 12°, 38°, 81°, and 37° respectively. The equivalence range was set at /
10°.RESULTS: 501 patient charts were abstracted from 10 sites. The average patient
age was 65 years; 76% were male. The 95% confidence interval (C.I.) fell within the
corresponding predefined equivalence range of / 10° for each of the 4 effective-
ness measures (with means of 12°, 37°, 81°, and 37° respectively.) The effectiveness
injections/joint rate was 1.080.32(n629 joints) with a 95% C.I. of 1.05 to 1.11, This
CI does not fall within the reported C.I. of 1.6 to 1.8 in published trials (p0.05). The
average number of (injection, manipulation, and follow-up) office visits/injection
was 2.921.05 (n620). CONCLUSIONS: CCH effectiveness findings were equiva-
lent to those published for the CORD-I clinical trial, yet the effectiveness injections/
joint rate was 36% lower than in the trial. Visits per injection cycle were also lower
than in the published CORD-I trial. The number of CCH injections used in real-
world settings may be lower because a) both patient/physician knew that active
drug was administered; b) anesthesia was used at manipulation; c) patient focused
treatment outcomes were used without the strict requirements of a clinical trial
protocol.
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